FORT WORTH, Texas--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced results from a new study presented at the ...
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon ® family of intraocular lenses ...
Clareon Vivity is the first and only non-diffractive extended depth of focus (EDOF) IOL with the wavefront-shaping X-WAVE Technology on Alcon’s most advanced lens platform1-6 Clareon Vivity joins ...
†Compared to CENTURION and CONSTELLATION Vision Systems. Based on bench data. **Based on worldwide unit sales of AcrySof® IQ Vivity and Clareon Vivity IOLs, as of Q4, 2024. “As ophthalmic practices ...
GENEVA--(BUSINESS WIRE)-- Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon ® PanOptix ® Pro intraocular lens (IOL) ...
FORT WORTH, Texas--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today new product launches in the U.S.
Alcon Inc. (NYSE:ALC) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Alcon Inc. (NYSE:ALC) announced the approval of the Clareon PanOptix Pro intraocular lens for patients in ...
The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the ...
Please provide your email address to receive an email when new articles are posted on . Alcon introduced the Clareon PanOptix Pro trifocal IOL, which will be commercially available in the U.S. in May, ...
Aging is a natural part of life, and as we grow older, our bodies go through various changes. Our hair turns gray, our joints ache a bit more and our energy levels fluctuate. But one aspect of aging ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results